Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SR1375 in Hospitalized Adult Patients With Community-acquired Pneumonia

NCT06577558 is registered in ClinicalTrials.gov with Shanghai SIMR Biotechnology Co., Ltd. as lead sponsor.

NCT NCT06577558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06577558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SR1375 in Hospitalized Adult Patients With Community-acquired Pneumonia
Lead sponsor
Shanghai SIMR Biotechnology Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
September 10, 2024
Completion date
October 30, 2025
Enrollment
240 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

community-acquired pneumonia